References: Identifying and treating comorbidities in people with psychoses including schizophrenia

  • Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry 2014;71(12):1350–63. https://www.ncbi.nlm.nih.gov/pubmed/25321337
  • Daumit GL, Dalcin AT, Dickerson FB, Miller ER, Evins AE, Cather C, et al. Effect of a comprehensive cardiovascular risk reduction intervention in persons with serious mental illness: A randomized clinical trial. JAMA Netw Open 2020;3(6):e207247. https://www.ncbi.nlm.nih.gov/pubmed/32530472
  • Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C, et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 2019;6(8):675–712. https://www.ncbi.nlm.nih.gov/pubmed/31324560
  • Fond G, Boyer L, Berna F, Godin O, Bulzacka E, Andrianarisoa M, et al. Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort. Br J Psychiatry 2018;213(2):464–70. https://www.ncbi.nlm.nih.gov/pubmed/29871707
  • Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016;50(5):410–72. https://www.ncbi.nlm.nih.gov/pubmed/27106681
  • Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 3: Update 2015 management of special circumstances: Depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry 2015;16(3):142–70. https://www.ncbi.nlm.nih.gov/pubmed/25822804
  • Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 2018;51(1-02):9–62. https://www.ncbi.nlm.nih.gov/pubmed/28910830
  • Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 2010;24(4 Suppl):81–90. https://www.ncbi.nlm.nih.gov/pubmed/20923923
  • Lambert TJ, Reavley NJ, Jorm AF, Oakley Browne MA. Royal Australian and New Zealand College of Psychiatrists expert consensus statement for the treatment, management and monitoring of the physical health of people with an enduring psychotic illness. Aust N Z J Psychiatry 2017;51(4):322–37. https://www.ncbi.nlm.nih.gov/pubmed/28343435
  • Morgan VA, Waterreus A, Jablensky A, Mackinnon A, McGrath JJ, Carr V, et al. People living with psychotic illness 2010: report on the second Australian national survey. Canberra: Australian Department of Health and Ageing; 2011. http://www.health.gov.au/internet/main/publishing.nsf/content/mental-pubs-p-psych10
  • Vancampfort D, Rosenbaum S, Probst M, Soundy A, Mitchell AJ, De Hert M, et al. Promotion of cardiorespiratory fitness in schizophrenia: a clinical overview and meta-analysis. Acta Psychiatr Scand 2015;132(2):131–43. https://www.ncbi.nlm.nih.gov/pubmed/25740655